Combinations Alliance

The Combinations Alliance, a Cancer Research UK model, aims to drive academic-industrial partnership, generating novel treatment options that would otherwise unlikely be realised. Novel combination ideas are generated and delivered via the UK’s Experimental Cancer Medicine Centre (ECMC) network of clinical and scientific experts working together to accelerate innovation in early-phase oncology research for patient benefit.

This model is aligned to the Cancer Research UK Research Strategy, and seeks novel agents from industry for investigation by ECMC researchers with hypothesis driven combination proposals in cancer including cancers of high unmet need and radiotherapy combinations. 

Why partner with us?

 

The Alliance facilitates access to world class scientists and medical centres and, importantly, creates an opportunity to explore combinations with some of the most promising investigational compounds currently in development. Being part of the Alliance significantly expands our potential to deliver transformative therapies to patients with many types of cancer.
Robert Forrester, Verastem

Collaborate with us

Our model of working with one expert adult and paediatric network of scientific and clinical excellence provides you with the opportunity to broaden your development pipeline with high quality off-critical path Phase Ib/IIa academic sponsored trials with other novel drugs or existing therapies, including radiotherapy. Combination ideas are generated and trials delivered through the ECMC network and supported by CRUK.


Work with us to explore the potential of your pipeline.